Company news
Cingulate Inc. news in 2024
Cingulate Inc.'s news releases, calls and decks from 2024, newest first.
Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000
December 22, 2024
Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market
November 6, 2024
Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301
September 11, 2024
Cingulate Announces Adjournment of Special Meeting
August 22, 2024
Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD
August 14, 2024
Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved
August 12, 2024
Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds
June 27, 2024
Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance
June 24, 2024
Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update
May 7, 2024
Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update
March 31, 2024
Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors
February 12, 2024
Cingulate Announces Closing of $7.5 Million Public Offering
February 5, 2024
Cingulate Announces Pricing of $7.5 Million Public Offering
February 1, 2024
Longtime Cingulate Controller Jennifer Callahan Promoted to CFO
January 28, 2024